RxDoctor Payments DataLook up a doctor →

Andreas Schmid, MD

Pulmonary Disease · Kansas City, KSNPI 1962663377

Payments from drug & device makers

$1,950,698in general payments, 2019–2025

Across 841 payments — averaging $2319.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$1.3M
  • Astrazeneca UK Limited$183K
  • Boehringer Ingelheim$178K
  • Verona Pharma, Inc.$96K
  • Mannkind Corporation$48K
  • AstraZeneca$39K
  • plus $105K from 5 others
$1,654in research payments, 2019–2025

Across 9 payments — averaging $183.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$2K

What the payments were for

  • Consulting fees$6,73326%
  • Speaking & faculty fees$15,30058%
  • Travel & lodging$3,28812%
  • Food & beverage$1,0584%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,950,698 in reported general payments places this provider in the 95th percentile of 92 pulmonary disease providers in Kansas.

See all pulmonary disease providers in Kansas

Medicare billing

Part B allowed, 2024
$74,956
Medicare patients
477
Services billed
1,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrikaftaElexacaftor/Tezacaftor/Ivacaft34$858,822
ArikayceAmikacin Liposomal/Neb.Accessr11$164,711
Dupixent PenDupilumab13$47,116
Spiriva RespimatTiotropium Bromide56$36,831
Stiolto RespimatTiotropium Br/Olodaterol Hcl53$28,775
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr40$17,801
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$17,290
SymbicortBudesonide/Formoterol Fumarate48$15,833
Breo ElliptaFluticasone/Vilanterol24$11,176
Ethambutol Hcl83$6,686
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate20$5,646
DuleraMometasone/Formoterol14$5,041
Advair HfaFluticasone Propion/Salmeterol12$4,802
Amikacin Sulfate13$3,026
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$2,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Insmed, Inc.Arikayce$1,300,493$164,71111 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$178,207$65,606109 claims
AstraZenecaSymbicort$38,796$15,83348 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 pulmonary disease providers in Kansas.

Other pulmonary disease in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →